Tuberculosis incidence rates during 8 years of follow-up of an antiretroviral treatment cohort in South Africa: comparison with rates in the community
Ankur Gupta, Robin Wood, Richard Kaplan, Linda-Gail Bekker, Stephen D Lawn, Ankur Gupta, Robin Wood, Richard Kaplan, Linda-Gail Bekker, Stephen D Lawn
Abstract
Background: Although antiretroviral therapy (ART) is known to be associated with time-dependent reductions in tuberculosis (TB) incidence, the long-term impact of ART on incidence remains imprecisely defined due to limited duration of follow-up and incomplete CD4 cell count recovery in existing studies. We determined TB incidence in a South African ART cohort with up to 8 years of follow-up and stratified rates according to CD4 cell count recovery. We compared these rates with those of HIV-uninfected individuals living in the same community.
Methodology/principal findings: Prospectively collected clinical data on patients receiving ART in a community-based cohort in Cape Town were analysed. 1544 patients with a median follow-up of 5.0 years (IQR 2.4-5.8) were included in the analysis. 484 episodes of incident TB (73.6% culture-confirmed) were diagnosed in 424 patients during 6506 person-years (PYs) of follow-up. The TB incidence rate during the first year of ART was 12.4 (95% CI 10.8-14.4) cases/100PYs and decreased to 4.92 (95% CI 3.64-8.62) cases/100PYs between 5 and 8 years of ART. During person-time accrued within CD4 cell strata 0-100, 101-200, 201-300, 301-400, 401-500, 501-700 and ≥700 cells/µL, TB incidence rates (95% CI) were 25.5 (21.6-30.3), 11.2 (9.4-13.5), 7.9 (6.4-9.7), 5.0 (3.9-6.6), 5.1 (3.8-6.8), 4.1 (3.1-5.4) and 2.7 (1.7-4.5) cases/100PYs, respectively. Overall, 75% (95% CI 70.9-78.8) of TB episodes were recurrent cases. Updated CD4 cell count and viral load measurements were independently associated with long-term TB risk. TB rates during person-time accrued in the highest CD4 cell count stratum (>700 cells/µL) were 4.4-fold higher that the rate in HIV uninfected individuals living in the same community (2.7 versus 0.62 cases/100PYs; 95%CI 0.58-0.65).
Conclusions/significance: TB rates during long-term ART remained substantially greater than rates in the local HIV uninfected populations regardless of duration of ART or attainment of CD4 cell counts exceeding 700 cells/µL.
Conflict of interest statement
Competing Interests: The authors have declared that no competing interests exist.
Figures
References
- World Health Organisation. Global tuberculosis control 2011. Geneva: World Health Organisation; 2011. WHO/HTM/TB/2011.16.
- Lawn SD, Harries AD, Williams BG, Chaisson RE, Losina E, et al. Antiretroviral therapy and the control of HIV-associated tuberculosis. Will ART do it? The International Journal of Tuberculosis and Lung Disease. 2011;15:571–581.
- World Health Organization. Guidelines for intensified tuberculosis case finding and isoniazid preventive therapy for people living with HIV in resource constrained settings. Geneva: World Health Organization; 2011.
- World Health Organization. Guidelines for implementing collaborative TB and HIV programme activities. Geneva: World Health Organization; 2003. WHO/CDS/TB/2003.319. WHO/HIV/2003.01.
- UN Joint Programme on HIV/AIDS. Global Report: UNAIDS Report on the Global AIDS Epidemic 2010. 2010. UNAIDS/10.11E | JC1958E.
- Lawn SD, Kranzer K, Wood R. Antiretroviral therapy for control of the HIV-associated tuberculosis epidemic in resource-limited settings. Clin Chest Med. 2009;30:685–699, viii.
- Dembele M, Saleri N, Carvalho AC, Saouadogo T, Hien AD, et al. Incidence of tuberculosis after HAART initiation in a cohort of HIV-positive patients in Burkina Faso. Int J Tuberc Lung Dis. 2010;14:318–323.
- Etard JF, Diouf A, De Beaudrap P, Akoi K, Ngom-Gueye NF, et al. Short and Long-Term Incidence of Tuberculosis and CD4-Cell Count Dynamic on HAART in Senegal. Open AIDS J. 2009;3:63–70.
- Hermans SM, Kiragga AN, Schaefer P, Kambugu A, Hoepelman AI, et al. Incident tuberculosis during antiretroviral therapy contributes to suboptimal immune reconstitution in a large urban HIV clinic in sub-Saharan Africa. PLoS One. 2010;5:e10527.
- Houlihan CF, Mutevedzi PC, Lessells RJ, Cooke GS, Tanser FC, et al. The tuberculosis challenge in a rural South African HIV programme. BMC Infectious Diseases. 2010;10:23.
- Lawn SD, Badri M, Wood R. Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort. AIDS. 2005;19:2109–2116.
- Lawn SD, Myer L, Edwards D, Bekker LG, Wood R. Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa. AIDS. 2009;23:1717–1725.
- Moore D, Liechty C, Ekwaru P, Were W, Mwima G, et al. Prevalence, incidence and mortality associated with tuberculosis in HIV-infected patients initiating antiretroviral therapy in rural Uganda. AIDS. 2007;21:713–719.
- Van Rie A, Westreich D, Sanne I. Tuberculosis in patients receiving antiretroviral treatment: incidence, risk factors, and prevention strategies. J Acquir Immune Defic Syndr. 2011;56:349–355.
- Nicholas S, Sabapathy K, Ferreyra C, Varaine F, Pujades-Rodriguez M. Incidence of tuberculosis in HIV-infected patients before and after starting combined antiretroviral therapy in 8 sub-Saharan African HIV programs. J Acquir Immune Defic Syndr. 2011;57:311–318.
- Bekker LG, Myer L, Orrell C, Lawn S, Wood R. Rapid scale-up of a community-based HIV treatment service: programme performance over 3 consecutive years in Guguletu, South Africa. S Afr Med J. 2006;96:315–320.
- Dawson R, Masuka P, Edwards DJ, Bateman ED, Bekker LG, et al. Chest radiograph reading and recording system: evaluation for tuberculosis screening in patients with advanced HIV. Int J Tuberc Lung Dis. 2010;14:52–58.
- Nglazi MD, Lawn SD, Kaplan R, Kranzer K, Orrell C, et al. Changes in programmatic outcomes during 7 years of scale-up at a community-based antiretroviral treatment service in South Africa. J Acquir Immune Defic Syndr. 2011;56:e1–8.
- World Health Organisation. Scaling up antiretroviral therapy in resource-limited settings: guidelines for a public health approach; Executive summary. Geneva: World Health Organisation; 2002.
- World Health Organisation. Improving the diagnosis and treatment of smear-negative pulmonary and extrapulmonary tuberculosis among adults and adolescents. Recommendations for HIV-prevalent and resource-constrained settings. Geneva: World Health Organisation; 2007.
- The South African Tuberculosis Control Programme. Practical Guidelines 2004. Available at URL: [Accessed 10th October 2011]
- National Department of Health, Republic of South Africa. Development of the district health information system. Available at URL: [Accessed 1st March 2011]
- Statistics South Africa. Mid-year population estimates. 2010; Available at URL: [Accessed 1st March 2011]
- Actuarial Society of South Africa. AIDS demographic model. 2008; Available at URL: [Accessed 15th July 2011]
- Wood R, Lawn SD, Caldwell J, Kaplan R, Middelkoop K, et al. Burden of new and recurrent tuberculosis in a major South African city stratified by age and HIV-status. PLoS One. 2011;6:e25098.
- Lawn SD, Fraenzel A, Kranzer K, Caldwell J, Bekker LG, et al. Provider-initiated HIV testing increases access of patients with HIV-associated tuberculosis to antiretroviral treatment. S Afr Med J. 2011;101:258–262.
- Lawn SD, Bekker LG, Wood R. How effectively does HAART restore immune responses to Mycobacterium tuberculosis? Implications for tuberculosis control. AIDS. 2005;19:1113–1124.
- Wood R, Liang H, Wu H, Middelkoop K, Oni T, et al. Changing prevalence of tuberculosis infection with increasing age in high-burden townships in South Africa. Int J Tuberc Lung Dis. 2010;14:406–412.
- Middelkoop K, Bekker LG, Liang H, Aquino LD, Sebastian E, et al. Force of tuberculosis infection among adolescents in a high HIV and TB prevalence community: a cross-sectional observation study. BMC Infect Dis. 2011;11:156.
- Crampin AC, Mwaungulu JN, Mwaungulu FD, Mwafulirwa DT, Munthali K, et al. Recurrent TB: relapse or reinfection? The effect of HIV in a general population cohort in Malawi. AIDS. 2010;24:417–426.
- Charalambous S, Grant AD, Moloi V, Warren R, Day JH, et al. Contribution of reinfection to recurrent tuberculosis in South African gold miners. Int J Tuberc Lung Dis. 2008;12:942–948.
- Wood R, Lawn SD, Johnstone-Robertson S, Bekker LG. Tuberculosis control has failed in South Africa–time to reappraise strategy. S Afr Med J. 2011;101:111–114.
- Ahoua L, Guenther G, Pinoges L, Anguzu P, Chaix M-L, et al. Risk factors for virological failure and subtherapeutic antiretroviral drug concentrations in HIV-positive adults treated in rural northwestern Uganda. BMC Infectious Diseases. 2008;9:81.
- El-Khatib Z, Ekström AM, Ledwaba J, Mohapi L, Laher F, et al. Viremia and drug resistance among HIV-1 patients on antiretroviral treatment – a cross-sectional study in Soweto, South Africa. AIDS. 2010;24:1679–1687.
- Lawn SD, Butera ST, Shinnick TM. Tuberculosis unleashed: the impact of human immunodeficiency virus infection on the host granulomatous response to Mycobacterium tuberculosis. Microbes Infect. 2002;4:635–646.
- Hosseinipour MC, Kumwenda JJ, Weigel R, Brown LB, Mzinganjira D, et al. Second-line treatment in the Malawi antiretroviral programme: high early mortality, but good outcomes in survivors, despite extensive drug resistance at baseline. HIV Med. 2010;11:510–518.
- Murphy RA, Sunpath H, Lu Z, Chelin N, Losina E, et al. Outcomes after virologic failure of first-line ART in South Africa. AIDS. 2010;24:1007–1012.
- Pujades-Rodriguez M, O'Brien D, Humblet P, Calmy A. Second-line antiretroviral therapy in resource-limited settings: the experience of Medecins Sans Frontieres. AIDS. 2008;22:1305–1312.
- World Health Organization. WHO policy on TB infection control in health-care facilities, congregate settings and households. Geneva: World Health Organization; 2009.
- Lawn SD, Kranzer K, Edwards DJ, McNally M, Bekker LG, et al. Tuberculosis during the first year of antiretroviral therapy in a South African cohort using an intensive pretreatment screening strategy. AIDS. 2010;24:1323–1328.
- Lawn SD, Brooks SV, Kranzer K, Nicol MP, Whitelaw A, et al. Screening for HIV-Associated Tuberculosis and Rifampicin Resistance before Antiretroviral Therapy Using the Xpert MTB/RIF Assay: A Prospective Study. PLoS Med. 2011;8:e1001067.
- Lawn SD, Kerkhoff A, Vogt M, Wood R. Screening for HIV-associated tubercolusis prior to antiretroviral therapy: diagnostic accuracy of a low-cost, urine antigen, point-of-care assay (Determine TB-LAM). The Lancet Infectious Diseases. 2011 doi: .
- Lawn SD, Wood R, De Cock KM, Kranzer K, Lewis JJ, et al. Antiretrovirals and isoniazid preventive therapy in the prevention of HIV-associated tuberculosis in settings with limited health-care resources. Lancet Infect Dis. 2010;10:489–498.
- Samandari T, Agizew TB, Nyirenda S, Tedla Z, Sibanda T, et al. 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial. Lancet. 2011;377:1588–1598.
- Golub JE, Pronyk P, Mohapi L, Thsabangu N, Moshabela M, et al. Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. AIDS. 2009;23:631–636.
- Golub JE, Saraceni V, Cavalcante SC, Pacheco AG, Moulton LH, et al. The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS. 2007;21:1441–1448.
- Boulle A, Van Cutsem G, Hilderbrand K, Cragg C, Abrahams M, et al. Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa. AIDS. 2010;24:563–572.
- Sanne IM, Westreich D, Macphail AP, Rubel D, Majuba P, et al. Long term outcomes of antiretroviral therapy in a large HIV/AIDS care clinic in urban South Africa: a prospective cohort study. J Int AIDS Soc. 2009;12:38.
- Egger M, Spycher BD, Sidle J, Weigel R, Geng EH, et al. Correcting mortality for loss to follow-up: a nomogram applied to antiretroviral treatment programmes in sub-Saharan Africa. PLoS Med. 2011;8:e1000390.
Source: PubMed